Micreos Pharmaceuticals

Micreos Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of targeted antibacterials based on endolysin technology. The company's proprietary platform produces engineered enzymes that specifically target and kill pathogenic bacteria, such as Staphylococcus aureus, while preserving the beneficial microbiome. Their lead program, XA-01, is being evaluated for the treatment of inflammatory skin conditions and cutaneous T-cell lymphoma. By providing a highly specific alternative to broad-spectrum antibiotics, Micreos aims to address the global challenge of antimicrobial resistance. The company operates as a specialized pharmaceutical entity that was spun out from the broader Micreos Group to focus on clinical development.